ORKA
Oruka Therapeutics Inc
NASDAQ · Biotechnology
$33.05
+1.63 (+5.19%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 372.50M | 351.85M | 301.99M |
| Net Income | -104,674,461 | -84,234,881 | -79,583,487 |
| EPS | — | — | — |
| Profit Margin | -28.1% | -23.9% | -26.4% |
| Rev Growth | -6.8% | +18.4% | +6.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 655.02M | 633.32M | 598.58M |
| Total Equity | 792.09M | 852.79M | 739.85M |
| D/E Ratio | 0.83 | 0.74 | 0.81 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -120,858,001 | -107,157,018 | -93,330,324 |
| Free Cash Flow | -75,919,374 | -55,757,162 | -73,499,960 |